EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
osimertinib + afatinib Sensitive: B - Late Trials
|
osimertinib + afatinib Sensitive: B - Late Trials
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
osimertinib Sensitive: C3 – Early Trials
|
osimertinib Sensitive: C3 – Early Trials
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
gefitinib Resistant: C3 – Early Trials
|
gefitinib Resistant: C3 – Early Trials
|
EGFR L858R + EGFR T790M
|
Lung Non-Small Cell Squamous Cancer
|
EGFR L858R + EGFR T790M
|
Lung Non-Small Cell Squamous Cancer
|
gefitinib Resistant: C4 – Case Studies
|
gefitinib Resistant: C4 – Case Studies
|
EGFR L858R + EGFR T790M
|
LUAD
|
EGFR L858R + EGFR T790M
|
LUAD
|
gefitinib Resistant: D – Preclinical
|
gefitinib Resistant: D – Preclinical
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
CH7233163 Sensitive: D – Preclinical
|
CH7233163 Sensitive: D – Preclinical
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
rociletinib Sensitive: D – Preclinical
|
rociletinib Sensitive: D – Preclinical
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
osimertinib + BX795 Sensitive: D – Preclinical
|
osimertinib + BX795 Sensitive: D – Preclinical
|
EGFR L858R + EGFR T790M
|
NSCLC
|
EGFR L858R + EGFR T790M
|
NSCLC
|
H002 Sensitive: D – Preclinical
|
H002 Sensitive: D – Preclinical
|
EGFR L858R + EGFR T790M
|
Lung Cancer
|
EGFR L858R + EGFR T790M
|
Lung Cancer
|
osimertinib + tipifarnib Sensitive: D – Preclinical
|
osimertinib + tipifarnib Sensitive: D – Preclinical
|